PASG

3.9208.59%
AM

Athena Maria Countouriotis

Independent Director

Dr. Athena Maria Countouriotis, M.D., is Director of Umoja BioPharma, Inc. from March 2026. Dr. Countouriotis is Director of Leal Therapeutics, Inc. She serves as Independent Director of BioMarin Pharmaceutical Inc. since December 27, 2023. She serves as Director of Recludix Pharma, Inc. and served as its Chairperson of the Board since September 2022 until July 2023. She serves as Director at Leal Therapeutics, Inc. Dr. Countouriotis is the Co-Founder of Avenzo Therapeutics, Inc. and serves as its Chief Executive Officer, President and Director and is its Chairperson of the Board. Dr. Countouriotis serves as a Board Chair at Capstan Therapeutics, Inc. since October 2022. She served as Chief Executive Officer at Turning Point Therapeutics, Inc. since September 2018 until August 2022. She was Director of Turning Point Therapeutics, Inc. from September 2018 to August 15, 2022. She has been Independent Director of Passage Bio, Inc since February 2020. She was President at Turning Point Therapeutics, Inc. since April 2019 until August 2022 and served as Interim Principal Financial Officer since May 14, 2021 until July 26, 2021. Dr. Countouriotis has been Independent Director of Iovance Biotherapeutics, Inc. since June 10, 2019. Dr. Countouriotis is the co-founder and Chief Executive Officer of Avenzo Therapeutics. Dr. Countouriotis joined Turning Point Therapeutics in May 2018 as Executive Vice President and Chief Medical Officer. Dr. Countouriotis was a Director of TrovaGene, Inc. since September 2017 until January 24, 2020. She was Chief Medical Officer and Senior Vice President of Adverum Biotechnologies, Inc. from June 19, 2017 to May 11, 2018. Dr. Countouriotis served as the Chief Medical Officer and Senior Vice President of Halozyme Therapeutics, Inc. from January 5, 2015 to May 5, 2017. Dr. Countouriotis served as the Chief Medical Officer of Ambit Biosciences Corporation from February 8, 2012 to January 2015. She led the continued clinical development of quizartinib (AC220), being evaluated in a Phase 2 clinical trial in acute myeloid leukemia (AML) and Ambit's additional clinical-stage programs AC430, an oral JAK2 inhibitor and AC480, a pan-HER inhibitor. Dr. Countouriotis served as a Global Clinical Leader within the oncology business unit at Pfizer Inc. She led late-stage clinical development for bosutinib and gemtuzumab ozogamicin. She led the preparation of regulatory submissions for approval of bosutinib in the U. S. and Europe, as well as discussions with regulatory agencies about development within leukemia worldwide. She served as a Clinical Leader at sunitinib. She served as a Clinical Team Director at Bristol-Myers Squibb in various leading clinical development roles for Sutent, Mylotarg, Bosulif and Sprycel. She began her career at Cell Therapeutics, Inc. with a focus on AML and non-Hodgkin's lymphoma. She received her initial training in pediatrics at the University of California, Los Angeles and additional training at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology/Oncology Program. She received a doctorate from Tufts University. Dr. Countouriotis received a B.S. in Physiology from the University of California, Los Angeles and an M.D. at Tufts University School of Medicine.

Positions